MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study (EPSOMIP2)

Linköping University (LiU)

Status: Invitation-only

Conditions: Hypertension; OSAS (Obstructive Sleep Apneas Syndrome); Cirrhosis; Obesity & Overweight; MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Type 2 Diabetes; Advanced Fibrosis; Sarcopenia; Metabolic Syndrome

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT07312136

2024-05471-01

Details and patient eligibility

About

The EPSOMIP2 (Evaluating the Prevalence and Severity Of MASLD In Primary care - a Follow-up Study) trial is a longitudinal cohort study of patients with type 2 diabetes recruited from primary health care centers in Östergötland, Sweden. Between 2019-2023, 317 patients were included and underwent rigorous clinical evaluation, vibration controlled transient elastography, biobanking of bloodsamples, and the latest magnetic resonance techniques to liver and body composition. All patients alive will be re-invited to undergo the same evaluation and additional tests.

Enrollment: 317 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previously included and fulfilled evaluation in EPSONIP trial (NCT03864510)
• Age >/= 18 years
• Informed consent

Exclusion criteria

• Contraindication to magnetic resonance
• Other primary liver disease than MASLD diagnosed after inclusion EPSONIP trial (NCT03864510)
• Liver transplantation